The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder

European Neuropsychopharmacology

Volumn 25, Issue 3, 2015, Pages 335-342

  Fountoulakis, Konstantinos N ^a   Gazouli, Maria ^b   Kelsoe, John ^c   Akiskal, Hagop ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biological models; Bipolar depression; Bipolar disorder; Lurasidone; Neurobiology

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; CALCIUM CHANNEL L TYPE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; FLUOXETINE; LURASIDONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; QUETIAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DRUG EFFICACY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SUPERSENSITIVITY; ANIMAL; MEDLINE; STATISTICS AND NUMERICAL DATA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; HUMANS; LURASIDONE HYDROCHLORIDE; MEDLINE;

EID: 84925941512     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.11.010     Document Type: Article

References (57)

1. Brugue E., Vieta E. A typical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:275-282.
2. Bymaster F.P., Felder C.C. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry 2002, 7(Suppl. 1):S57-63.
3. Caccia S., Pasina L., Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr. Dis. Treat. 2012, 8:155-168.
4. Calabrese J., Hirschfeld R.M., Frye M.A. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J. Clin. Psychiatry 2004, 65:1499-1504.
5. Cates L.N., Roberts A.J., Huitron-Resendiz S., Hedlund P.B. Effects of lurasidone in behavioral models of depression. Role of the 5-HT(7) receptor subtype. Neuropharmacology 2013, 70:211-217.
6. Cruz M.P. Lurasidone HCl (Latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with schizophrenia. Pharm. Ther. 2011, 36:489-492.
7. Cruz N., Sanchez-Moreno J., Torres F., Goikolea J.M., Valenti M., Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int. J. Neuropsychopharmacol. 2010, 13:5-14.
8. Davis K.L., Berger P.A. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol. Psychiatry 1978, 13:23-49.
9. Davis K.L., Hollister L.E., Berger P.A., Barchas J.D. Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation. Psychopharmacol. Commun. 1975, 1:533-543.
10. Fountoulakis K.N., Gonda X., Vieta E., Rihmer Z. Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?. Ann. Gen. Psychiatry 2011, 10:8.
11. Fountoulakis K.N., Grunze H., Panagiotidis P., Kaprinis G. Treatment of bipolar depression: an update. J. Affect. Disord. 2007.
12. Fountoulakis K.N., Kasper S., Andreassen O., Blier P., Okasha A., Severus E., Versiani M., Tandon R., Moller H.J., Vieta E. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262(Suppl. 1):1-48.
13. Fountoulakis K.N., Kelsoe J.R., Akiskal H. Receptor targets for antidepressant therapy in bipolar disorder: an overview. J. Affect. Disord. 2012, 138:222-238.
14. Fountoulakis K.N., Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int. J. Neuropsychopharmacol. 2008, 11:999-1029.
15. Fountoulakis K.N., Vieta E., Sanchez-Moreno J., Kaprinis S.G., Goikolea J.M., Kaprinis G.S. Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord. 2005, 86:1-10.
16. Fountoulakis K.N., Vieta E., Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. J. Affect. Disord. 2011, 133:361-370.
17. Fountoulakis K.N., Vieta E., Siamouli M., Valenti M., Magiria S., Oral T., Fresno D., Giannakopoulos P., Kaprinis G.S. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann. Gen. Psychiatry 2007, 6:27.
18. Fritze J. The adrenergic-cholinergic imbalance hypothesis of depression: a review and a perspective. Rev. Neurosci. 1993, 4:63-93.
19. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 2000, 22:642-649.
20. Guay D.R. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. Consult Pharm. 2011, 26:579-582.
21. Hopkins C.R. ACS chemical neuroscience molecule spotlight on latuda (lurasidone; SM-13,496). ACS Chem. Neurosci. 2011, 2:58-59.
22. Horisawa T., Ishibashi T., Nishikawa H., Enomoto T., Toma S., Ishiyama T., Taiji M. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav. Brain Res. 2011, 220:83-90.
23. Horisawa T., Ishiyama T., Ono M., Ishibashi T., Taiji M. Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradiography. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 40:132-137.
24. Horisawa T., Nishikawa H., Toma S., Ikeda A., Horiguchi M., Ono M., Ishiyama T., Taiji M. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone. Behav. Brain Res. 2013, 244:66-69.
25. Huang M., Horiguchi M., Felix A.R., Meltzer H.Y. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 2012, 23:436-440.
26. Ichikawa O., Okazaki K., Nakahira H., Maruyama M., Nagata R., Tokuda K., Horisawa T., Yamazaki K. Structural insight into receptor-selectivity for lurasidone. Neurochem. Int. 2012, 61:1133-1143.
27. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., Matsumoto K., Nishikawa H., Ueda Y., Toma S., Oki H., Tanno N., Saji I., Ito A., Ohno Y., Nakamura M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010, 334:171-181.
28. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 2007, 572:160-170.
29. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine[U+05F3]s antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
30. Judd L.L., Akiskal H.S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 2003, 73:123-131.
31. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., Keller M.B. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch. Gen. Psychiatry 1998, 55:694-700.
32. Judd L.L., Akiskal H.S., Schettler P.J., Endicott J., Maser J., Solomon D.A., Leon A.C., Rice J.A., Keller M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 2002, 59:530-537.
33. Loebel A., Cucchiaro J., Silva R., Kroger H., Hsu J., Sarma K., Sachs G. Lurasidone monotherapy in the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2013.
34. Meyer J.M., Loebel A.D., Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin. Investig. Drugs 2009, 18:1715-1726.
35. Murai T., Nakako T., Ikeda K., Ikejiri M., Ishiyama T., Taiji M. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behav. Brain Res. 2014, 261:26-30.
36. Nakazawa S., Yokoyama C., Nishimura N., Horisawa T., Kawasaki A., Mizuma H., Doi H., Onoe H. Evaluation of dopamine D(2)/D(3) and serotonin 5-HT(2)A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography. Psychopharmacology (Berl) 2013, 225:329-339.
37. Pacchiarotti I., Bond D.J., Baldessarini R.J., Nolen W.A., Grunze H., Licht R.W., Post R.M., Berk M., Goodwin G.M., Sachs G.S., Tondo L., Findling R.L., Youngstrom E.A., Tohen M., Undurraga J., Gonzalez-Pinto A., Goldberg J.F., Yildiz A., Altshuler L.L., Calabrese J.R., Mitchell P.B., Thase M.E., Koukopoulos A., Colom F., Frye M.A., Malhi G.S., Fountoulakis K.N., Vazquez G., Perlis R.H., Ketter T.A., Cassidy F., Akiskal H., Azorin J.M., Valenti M., Mazzei D.H., Lafer B., Kato T., Mazzarini L., Martinez-Aran A., Parker G., Souery D., Ozerdem A., McElroy S.L., Girardi P., Bauer M., Yatham L.N., Zarate C.A., Nierenberg A.A., Birmaher B., Kanba S., El-Mallakh R.S., Serretti A., Rihmer Z., Young A.H., Kotzalidis G.D., MacQueen G.M., Bowden C.L., Ghaemi S.N., Lopez-Jaramillo C., Rybakowski J., Ha K., Perugi G., Kasper S., Amsterdam J.D., Hirschfeld R.M., Kapczinski F., Vieta E. The international society for bipolar disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 2013, 170:1249-1262.
38. Post R.M. The impact of bipolar depression. J. Clin. Psychiatry 2005, 66:5-10.
39. Potkin S.G., Keator D.B., Kesler-West M.L., Nguyen D.D., van Erp T.G., Mukherjee J., Shah N., Preda A. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2014, 19:176-181.
40. Rosa A.R., Fountoulakis K., Siamouli M., Gonda X., Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci Ther. 2011, 17:167-177.
41. Rubin L.S. Patterns of adrenergic-cholinergic imbalance in the functional psychoses. Psychol. Rev. 1962, 69:501-519.
42. Seager M.A., Barth V.N., Phebus L.A., Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl) 2005, 181:126-133.
43. Seager M.A., Huff K.D., Barth V.N., Phebus L.A., Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol. Psychiatry 2004, 55:1103-1109.
44. Siever L.J., Risch S.C., Murphy D.L. Central cholinergic-adrenergic imbalance in the regulation of affective state. Psychiatry Res. 1981, 5:108-109.
45. Tarazi F.I., Baldessarini R.J., Kula N.S., Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 2003, 306:1145-1151.
46. Tarazi F.I., Riva M.A. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert Opin. Drug Discov. 2013, 8:1297-1307.
47. Thase M.E., Jonas A., Khan A., Bowden C.L., Wu X., McQuade R.D., Carson W.H., Marcus R.N., Owen R. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 2008, 28:13-20.
48. Tohen M., Katagiri H., Fujikoshi S., Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J. Affect. Disord. 2013, 149:196-201.
49. Tohen M., McDonnell D.P., Case M., Kanba S., Ha K., Fang Y.R., Katagiri H., Gomez J.C. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br. J. Psychiatry: J. Mental Sci. 2012, 201:376-382.
50. Vieta E. Long-term treatment of bipolar depression and other issues. J. Clin. Psychiatry 2010, 71:e07.
51. Vieta E. Role of antidepressants in bipolar depression. J. Clin. Psychiatry 2010, 71:e21.
52. Vieta E., Locklear J., Gunther O., Ekman M., Miltenburger C., Chatterton M.L., Astrom M., Paulsson B. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J. Clin. Psychopharmacol. 2010, 30:579-590.
53. Wiste A.K., Arango V., Ellis S.P., Mann J.J., Underwood M.D. Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder. Bipolar Disord. 2008, 10:349-359.
54. Wong D.F., Kuwabara H., Brasic J.R., Stock T., Maini A., Gean E.G., Loebel A. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl) 2013, 229:245-252.
55. Yatham L.N., Goldstein J.M., Vieta E., Bowden C.L., Grunze H., Post R.M., Suppes T., Calabrese J.R. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry 2005, 66(Suppl. 5):40-48.
56. Young L.T., Warsh J.J., Kish S.J., Shannak K., Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol. Psychiatry 1994, 35:121-127.
57. Yudofsky S. Adrenergic-cholinergic imbalance in affective disorders. Lancet 1976, 2:1342-1343.